drugset / Trial / NCT05485883
Tislelizumab Plus Lenvatinib in Stage III-IV RCC
NaSingle-groupOpen-labelTreatment
Summary
This is a phase II study to determine the efficacy and safety of Tislelizumab when given in combination with Lenvatinib as treatment for patients with the advanced kidney cancer . Patients will receive treatment with Tislelizumab in combination with Lenvatinib every 3 weeks unitl tumor progression or serious side effects
Timeline
- Start
- 2022-07-01
- Primary completion
- 2023-12-31
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenvatinib | Small molecule | 8 mg | — |
| Subject | Tislelizumab | Monoclonal antibody | — | — |